BCC-One-Stop-Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Augsburg

About this trial

Basal cell carcinoma (BCC) is the most common malignant skin tumour. The standard treatment is micrographically controlled surgery (MMS), which achieves high cure rates but requires considerable time and personnel. A key problem is the inadequate preoperative determination of tumour margins, which often leads to multiple cycles of excision.

The aim of this multicentre, prospective, randomised controlled intervention study is to evaluate line-field confocal optical coherence tomography (LC-OCT) for preoperative margin determination in BCC within the framework of MMS.

Research question:

Can preoperative LC-OCT-assisted margin marking increase the efficiency of MMS by reducing the number of excision cycles required without compromising oncological safety?

Methodology:

Approximately 290 patients with histologically confirmed BCC will be enrolled at five German centres and randomly assigned to either standard MMS or MMS with upstream LC-OCT margin determination. In the intervention group, the excision margin will be specifically extended if a tumour is detected in the LC-OCT.

Primary endpoint:

Number of MMS cycles required to achieve R0 resection.

Secondary endpoints:

Total duration of surgery, size of surgical defect, cosmetic outcome (POSAS), patient satisfaction and stress, sensitivity and specificity of LC-OCT compared to histopathology.

Significance:

The study addresses the clinical conflict of objectives between complete tumour removal and maximum tissue preservation. Successful implementation could optimise MMS through modern imaging, conserve surgical resources and improve patient care in the long term.

Eligibility criteria

Qualifiers

Adults (≥18 years) with basal cell carcinoma (BCC) scheduled for Mohs micrographic surgery (MMS),

Diagnosis confirmed by dermoscopy and histopathology or optical coherence tomography (OCT),

No limitation regarding tumor size or BCC subgroups.

Disqualifiers

Poor LC-OCT image quality,

Incomplete adherence to the study protocol,

Previous treatment of the BCC,

Anatomical sites that are difficult to access with LC-OCT (e.g., inner ear, medial canthus of the eye).

Trial design

Treatments tested in this trial

  • Margin Mapping with Line-field confocal optical coherence tomography

Treatment groups

290 Participants
are divided into 2 treatment groups

Sponsors and collaborators